Recently, a systemic review and meta-analysis was performed to determine whether FDCs are effective in treating TB, and the results showed a trend toward higher risk of treatment failure or relapse with FDC use (pooled relative risk, 1.28; 95% CI, 0.99-1.7) 36 .
← all excerpts
Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.
1
—
—